Home › Research › Risk factors
Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance
Alison Myoraku, Isabella Hausle, Marta Milà‐Alomà, Pamela Thropp, Laura A. Wang, Pudugramam Murali Doraiswamy, Duygu Tosun. The Journal of Prevention of Alzheimer s Disease, 2025-11-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
ADI groups differed by sex, ethnoracial background, and MMSE scores. The intermediately disadvantaged group had 1.55 times higher odds of being amyloid PET positive compared to the least disadvantaged group. While this group also showed higher levels of plasma p-tau217/Aβ42 and p-tau217, these differences were no longer significant after accounting for the higher prevalence of amyloid positivity. Critically, the predictive accuracy of all three BBMs for amyloid PET status did not differ across the ADI groups. The p-tau217/Aβ42 ratio performed best, yielding the fewest indeterminate cases in a two-cut-point classification model. The diagnostic performance of plasma AD biomarkers is robust and is not compromised by neighborhood-level disadvantage. These findings support the generalizability and equitable clinical utility of biomarkers like p-tau217/Aβ42 for AD diagnosis across diverse socioeconomic settings.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 755 participants. This study found that the accuracy of blood-based biomarkers for amyloid PET status did not differ across neighborhood disadvantage groups, supporting their use across socioeconomic settings. It is about diagnosis, not about treating, curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Myoraku, A., Hausle, I., Milà‐Alomà, M., Thropp, P., Wang, L. A., Doraiswamy, P. M., et al. (2025). Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100445
Vancouver
Myoraku A, Hausle I, Milà‐Alomà M, Thropp P, Wang LA, Doraiswamy PM, et al. Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100445. PMID: 41285652.
BibTeX
@article{myoraku2025-41285652,
author = {Myoraku, Alison and Hausle, Isabella and Milà‐Alomà, Marta and Thropp, Pamela and Wang, Laura A. and Doraiswamy, Pudugramam Murali and Tosun, Duygu},
title = {{Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance}},
journal = {The Journal of Prevention of Alzheimer s Disease},
year = {2025},
doi = {10.1016/j.tjpad.2025.100445},
pmid = {41285652},
url = {https://doi.org/10.1016/j.tjpad.2025.100445}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- ADI groups differed by sex, ethnoracial background, and MMSE scores.
- The intermediately disadvantaged group had 1.55 times higher odds of being amyloid PET positive compared to the least disadvantaged group.
- While this group also showed higher levels of plasma p-tau217/Aβ42 and p-tau217, these differences were no longer significant after accounting for the higher prevalence of amyloid positivity.
- Critically, the predictive accuracy of all three BBMs for amyloid PET status did not differ across the ADI groups.
- The p-tau217/Aβ42 ratio performed best, yielding the fewest indeterminate cases in a two-cut-point classification model.
Why it matters
This study found that the accuracy of blood-based biomarkers for amyloid PET status did not differ across neighborhood disadvantage groups, supporting their use across socioeconomic settings. It is about diagnosis, not about treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Study designcohort study
- Participants755
- Evidence strengthModerate
How this study scored 51/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 755 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41285652) |
| Free to read | 2 / 2 | Free to read |
| Points | 49 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2025.100445
- PubMed: 41285652
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Risk factors from nearby years
Also in Risk factors
388 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.